Unmet Need

With so many individuals at risk for HIV, why aren’t more being prescribed a PrEP medication?

Learn about HIV prevalence and risk factors.

Uptake of PrEP use in the United States remains low despite significant HIV risk1

Nearly
1 million
cisgender males had an indication
for a PrEP medication by 2020

Icon for total cisgender males indicated for PrEP (pre-exposure prophylaxis) and those with prescription

However, only 26%
of these patients were prescribed
a PrEP medication2

Among MSM diagnosed with HIV in 2019,3

38%

were Black MSM

and

32%

were Latino MSM

Yet, in a 2017 CDC study of PrEP use among MSM at risk (n=4056), only4

6%

were Black MSM

and

8%

were Latino MSM

Transgender women who are at risk for HIV may benefit from PrEP medication

A study conducted between 2019 and 2020 in Atlanta, Los Angeles, New Orleans, New York City, Philadephia, Seattle, and San Francisco (n=1608) found that5

42%

(n=659/1561) of TGW were HIV positive

and only

32%

(n=288/902) of HIV-negative TGW were on a PrEP medication

Help meet HIV risk head-on—talk to your appropriate patients about DESCOVY FOR PrEP®.

CDC=Centers for Disease Control and Prevention; MSM=men who have sex with men; TGW=transgender women (who have sex with men).